TENX — Tenax Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $6.75m
- -$4.22m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 6.89 | 8.56 | 9.87 | 32.7 | 11.1 |
Operating Profit | -6.89 | -8.56 | -9.87 | -32.7 | -11.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.81 | -8.39 | -9.85 | -33 | -11 |
Net Income After Taxes | -6.81 | -8.39 | -9.85 | -33 | -11 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.81 | -8.39 | -9.85 | -33 | -11 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.1 | -8.39 | -9.85 | -33 | -11 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -14,462 | -2,168 | -2,125 | -2,565 | -601 |